Abstract:Background: Autoimmune pulmonary alveolar proteinosis (aPAP) results from impaired macrophage-mediated clearance of alveolar surfactant lipoproteins. Whole lung lavage has been the first-line treatment but recent reports suggest the efficacy of granulocyte–macrophage colony-stimulating factor (GM-CSF). We aimed to review the efficacy and safety of nebulised GM-CSF in aPAP. Methods: We conducted a systematic review and meta-analysis searching Embase, CINAHL, MEDLINE and Cochrane Collaborative databases (1946–1 April 2022). Studies included patients aged >18 years with aPAP receiving nebulised GM-CSF treatment and a comparator cohort. Exclusion criteria included secondary or congenital pulmonary alveolar proteinosis, GM–CSF allergy, active infection or other serious medical conditions. The protocol was prospectively registered with PROSPERO (CRD42021231328). Outcomes assessed were St George's Respiratory Questionnaire (SGRQ), 6-min walk test (6MWT), gas exchange (diffusing capacity of the lung for carbon monoxide ( D LCO ) % predicted) and arterial–alveolar oxygen gradient. Results: Six studies were identified for review and three for meta-analysis, revealing that SGRQ score (mean difference −8.09, 95% CI −11.88– −4.3, p<0.0001), functional capacity (6MWT) (mean difference 21.72 m, 95% CI −2.76–46.19 m, p=0.08), gas diffusion ( D LCO % predicted) (mean difference 5.09%, 95% CI 2.05–8.13%, p=0.001) and arterial–alveolar oxygen gradient (mean difference −4.36 mmHg, 95% CI −7.19– −1.52 mmHg, p=0.003) all significantly improved in GM-CSF-treated patients with minor statistical heterogeneity (I 2 =0%). No serious trial-related adverse events were reported. Conclusions: Patients with aPAP treated with inhaled GM-CSF demonstrated significant improvements in symptoms, dyspnoea scores, lung function, gas exchange and radiology indices after treatment with nebulised GM-CSF of varying duration. There is an important need to review comparative effectiveness and patient choice in key clinical outcomes between the current standard of care, whole lung lavage, with the noninvasive treatment of nebulised GM-CSF in aPAP.

[The Pulmonary Expression of Granulocyte-Macrophage Colony-Stimulating Factor and Surfactant Protein in Adult Idiopathic Pulmonary Alveolar Proteinosis].

Pulmonary alveolar proteinosis in China: a systematic review of 241 cases.

Biochemical Index and Immunological Function in the Peripheral Blood of Patients with Idiopathic Pulmonary Alveolar Proteinosis

Clinical features of pulmonary alveolar proteinosis: experience with 12 cases and literature review

Pulmonary Alveolar Proteinosis in China: A Systematic Review of 241 Cases

The Ultrastructrual Observation of Pulmonary Alveolar Proteinosis

[Diagnostic Investigation of the Detection of Granulocyte-Macrophage Colony Stimulating Factor Antibody in Serum for Pulmonary Alveolar Proteinosis].

[Effectiveness and Safety of Inhaled Granulocyte-Macrophage Colony-Stimulating Factor Therapy in Idiopathic Pulmonary Alveolar Proteinosis].

Alveolar Macrophages in Pulmonary Alveolar Proteinosis: Origin, Function, and Therapeutic Strategies

Therapeutic efficacy of GM-CSF inhalation in patients with recurrent pulmonary alveolar proteinosis

Therapeutic Effect of Subcutaneous Injection of Low Dose Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Pulmonary Alveolar Proteinosis

Occupational Inhalational Exposure and Serum Gm-Csf Autoantibody in Pulmonary Alveolar Proteinosis

Pulmonary alveolar proteinosis caused by deletion of the GM-CSFRalpha gene in the X chromosome pseudoautosomal region 1

An exploratory study investigating biomarkers associated with autoimmune pulmonary alveolar proteinosis (aPAP)

Nebulised granulocyte–macrophage colony-stimulating factor (GM-CSF) in autoimmune pulmonary alveolar proteinosis: a systematic review and meta-analysis

Elderly-onset hereditary pulmonary alveolar proteinosis and its cytokine profile

Clinical Characteristics of Pulmonary Alveolar Proteinosis

[The Clinical Significance of the Levels of Serum KL-6 Mucin and Interleukin-13 in Pulmonary Alveolar Proteinosis].

A New Scale to Assess the Severity and Prognosis of Pulmonary Alveolar Proteinosis

Clinical Analysis of 7 Patients with Pulmonary Alveolar Proteinosis

Alveolar macrophage lipid burden correlates with clinical improvement in patients with Pulmonary Alveolar Proteinosis